RELVIZLYN Trademark

Trademark Overview


On Thursday, July 6, 2017, a trademark application was filed for RELVIZLYN with the United States Patent and Trademark Office. The USPTO has given the RELVIZLYN trademark a serial number of 87518531. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, February 15, 2021. This trademark is owned by Eli Lilly and Company. The RELVIZLYN trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations namely, pharmaceutical preparations for the treatment of Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hypoglycemia, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, Parkinson's disease, Psoriatic arthritis, rheumatoid arthritis, Sjogren's syndrome, sleep disorders, spondyloarthropathy, systemic lupus erythematosus, ulcerative colitis; Diagnostic agents a...
relvizlyn

General Information


Serial Number87518531
Word MarkRELVIZLYN
Filing DateThursday, July 6, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, February 15, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 14, 2017

Trademark Statements


Goods and ServicesPharmaceutical preparations namely, pharmaceutical preparations for the treatment of Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hypoglycemia, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, Parkinson's disease, Psoriatic arthritis, rheumatoid arthritis, Sjogren's syndrome, sleep disorders, spondyloarthropathy, systemic lupus erythematosus, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, July 13, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Tuesday, February 16, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, February 15, 2021ABANDONMENT - NO USE STATEMENT FILED
Friday, June 19, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 18, 2020EXTENSION 5 GRANTED
Wednesday, June 17, 2020EXTENSION 5 FILED
Wednesday, June 17, 2020TEAS EXTENSION RECEIVED
Wednesday, December 11, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, December 9, 2019EXTENSION 4 GRANTED
Monday, December 9, 2019EXTENSION 4 FILED
Monday, December 9, 2019TEAS EXTENSION RECEIVED
Wednesday, June 19, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 17, 2019EXTENSION 3 GRANTED
Monday, June 17, 2019EXTENSION 3 FILED
Monday, June 17, 2019TEAS EXTENSION RECEIVED
Friday, December 14, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 12, 2018EXTENSION 2 GRANTED
Wednesday, December 12, 2018EXTENSION 2 FILED
Wednesday, December 12, 2018TEAS EXTENSION RECEIVED
Thursday, June 28, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 27, 2018EXTENSION 1 GRANTED
Monday, June 25, 2018EXTENSION 1 FILED
Wednesday, June 27, 2018CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, June 25, 2018TEAS EXTENSION RECEIVED
Tuesday, January 9, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 14, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 14, 2017PUBLISHED FOR OPPOSITION
Wednesday, October 25, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Saturday, September 30, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, September 30, 2017ASSIGNED TO EXAMINER
Thursday, July 13, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, July 10, 2017NEW APPLICATION ENTERED IN TRAM